Market Newsdesk

MILWAUKEE, Nov. 24, 2020 (GLOBE NEWSWIRE) — Insurance technology provider, Zywave, today announced the acquisition of Insurance Technologies Corporation (ITC), a leading provider of marketing, rating, and management software and services to the insurance industry. Together with Zywave’s existing portfolio of solutions, the acquisition solidifies Zywave’s position as the leading provider of solutions for carriers and independent insurance agencies to help them drive business efficiency and accelerate growth.

“Zywave and ITC share the same goal—to provide the absolute best tech solutions to help insurance professionals succeed in the modern marketplace,” said Jason Liu, chief executive officer of Zywave. “With the combined offerings of our two companies, we are beyond excited to bring the most expansive and innovative tools to any agency selling any type of coverage – benefits, commercial or personal lines.”

Founded in 1983, ITC is headquartered in Carrollton, Texas, and serves more than 250 insurance companies and more than 9,000 agencies. The company’s products, all of which enable agency growth through greater efficiency and automation, include:

• Agency Marketing
  Services &
  Solutions – A comprehensive digital agency marketing offering that includes website design, marketing communication automation, SEO and SEM, custom content services and social media services.
• Personal Lines Comparative Rater – A highly accurate, web-based personal lines rater that automates the quoting process and enables users to automatically receive multiple quotes instantly, currently powering more than 30 million unique quotes per year.
• Agency Management
  System – The browser-based Agency Matrix agency management system (AMS) provides the foundation for P&C agency operations, increasing operational efficiency and simplifying day-to-day activities.

Zywave plans to align and integrate ITC’s products with its Sales Cloud offering, which includes multiple front-of-office solutions that streamline mission-critical workflows to strengthen organic growth. Within the Sales Cloud, ITC’s personal lines rating solution will be a natural complement to Zywave’s exclusive suite of existing market-leading CPQ offerings that enable more efficient and accurate quoting and proposals for employee benefits and commercial lines quoting.

ITC’s AMS will supplement Zywave’s current AMS offering for employee benefits agencies with new options for the management of operations at insurance agencies offering personal and commercial insurance. Additionally, integrations with Zywave’s Content Cloud will provide further differentiation and value to all areas of ITC’s existing product portfolio.

“ITC’s insurance solutions definitively round out our Sales Cloud with the most robust offering on the market,” added Liu. “We are excited to expand our services to provide solutions that meaningfully change how independent agencies operate, regardless of their specialty.”

“Our partnership with Zywave marks a truly monumental moment for our joint businesses,” said Laird Rixford, chief executive officer of ITC. “Combined, our solutions have the potential to not only help insurance providers compete in the digital marketplace, but thrive in all aspects of selling and servicing the insurance consumer. ITC takes pride in the high level of support we offer our clients and remain committed to that support as we enter the next chapter.”

Together with Zywave’s expansive client base, the ITC acquisition means the joint entity will serve more than 15,000 insurance organizations globally. This acquisition marks Zywave’s largest to date and fifth in just over two years, reinforcing Zywave’s continued commitment to investing in the insurance industry. Earlier this month, Zywave announced the acquisition of Advisen, the foremost provider of data, media and technology solutions for the commercial property and casualty insurance market. The Advisen acquisition coincided with the announcement of Zywave’s new investor relationship with Clearlake Capital Group, L.P. who shares Zywave’s vision to invest in the long-term strategic growth of the company, both organically and through M&A.

“Zywave is committed to bringing industry’s best tech to our partners, empowering them with the tools they need to grow their business,” said Liu. “We will continue to both invest in our existing products, while also enhancing our product portfolio with new acquisitions. At the same time, we are committed to providing extensive technical support and consultative services to our partners to help them succeed.”

For more information on Zywave, visit www.Zywave.com.

About ITC

Insurance Technologies Corporation (ITC), founded in 1983, provides websites, agency marketing, comparative rating, and management software and services to the insurance industry, including independent agents and insurance carriers. Headquartered in Carrollton, Texas, ITC is the largest provider of insurance agency websites in the United States and powers more than two million monthly auto and home quotes through its comparative rater TurboRater. Currently, ITC serves more than 250 insurance companies and more than 9,000 agencies. For more information, visit us online at GetITC.com. 

About Zywave  
Zywave leads the insurance tech industry, fueling business growth for its partners with cloud-based sales management, client delivery, content and analytics solutions. Offering a technology platform embedded with robust data and the most comprehensive content portfolio available, we empower smarter business decisions throughout the entire customer lifecycle. More than 6,000 carriers, HCM service providers, agencies and brokerages worldwide—including all of the top 100 U.S. insurance firms—use Zywave solutions to enhance client services, achieve business growth and promote greater health, wellness and safety. Additional information can be found at www.zywave.com. 

Contact: April Larsen
[email protected]
414-918-0547

VANCOUVER, British Columbia, Nov. 24, 2020 (GLOBE NEWSWIRE) — Siyata Mobile Inc. (NasdaqCM: SYTA, SYTAW) (“Siyata” or the “Company”) is pleased to announce it has entered into a distribution agreement with pei tel Communications GmbH, a distributor based in Germany, for its Siyata UV350. pei tel’s distribution countries include Germany, Austria, Switzerland, Belgium, Netherlands, and Luxembourg.

pei tel, a company of the Peiker family, specializes in developing and producing high-quality communication solutions and radio accessories for the commercial vehicle market. Its extensive product range includes various types of microphones, handsets, speakers, voice units and microphone speakers along with additional headsets. pei tel are also a master distributor for Motorola Solutions and are very active in the Push-to-Talk over Cellular space.

Marc Seelenfreund, CEO of Siyata Mobile states, “We are extremely excited to partner with pei tel to expand our Siyata UV350 offering to new market verticals in Europe. This is a fantastic opportunity for Siyata to engage with new European clientele in an effort to become a leading global vendor of innovative cellular devices for enterprise customers.”

Thomas Martin, CEO of pei tel, states, “As a full-range provider of professional communication technology equipment we’re constantly looking for high-quality products that will enrich our wide product portfolio. Thus, we are very happy to be partnering with Siyata Mobile. The agreement gives us the great opportunity to upgrade our product range of broadband solutions and offer a well proven premium device – the Siyata UV350 – to our markets.”

pei tel will show the Siyata UV350 for the first time on its virtual booth at the digitalPMRExpo, a European trade fair for secure communications, from Tuesday, November 24 to 26, 2020. To visit pei tel in its virtual booth, get your free ticket at www.pmrexpo.de/en/tickets.

About Siyata

Siyata Mobile Inc. is a B2B global vendor of next generation Push-To-Talk over Cellular (PTT) devices and cellular booster systems. Its portfolio of in-vehicle and rugged smartphones enable first responders and enterprise workers to instantly communicate, over a nationwide cellular network of choice, to improve communication, increase situational awareness and save lives.

Its portfolio of enterprise cellular booster systems enables first responders and enterprise workers to amplify its cellular signal in remote areas, inside structural buildings where signals are weak and within vehicles for maximum cellular signal strength possible.

Visit www.siyatamobile.com and http://www.unidencellular.com/ to learn more.

On Behalf of the Board of Directors of:
SIYATA MOBILE INC.
Marc Seelenfreund
CEO

Investor Relations:

Trevor Brucato, Managing Director
RBMG (RB Milestone Group LLC)
[email protected]

Sales Department:

Glenn Kennedy, VP Sales
Siyata Mobile Inc.
+1 416-892-1823
[email protected]

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on Siyata’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Siyata could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Siyata’s filings with the Securities and Exchange Commission (“SEC”), and in any subsequent filings with the SEC. Except as otherwise required by law, Siyata undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release.

SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) — Principia Biopharma Inc., a Sanofi company, focused on developing treatments for immune mediated diseases, today announced it has completed patient enrollment into the global Phase 3 PEGASUS trial for rilzabrutinib, an oral investigational Bruton tyrosine kinase (BTK) inhibitor. 

“We are pleased with the speed of recruitment and would like to thank investigators and study coordinators, and most importantly the patients who are volunteering to be part of a potential groundbreaking clinical trial,” said Dolca Thomas, MD, chief medical officer at Principia.  “Since there continues to be a significant need for treatment options among pemphigus patients, we are very encouraged by the interest in the trial.”

About PEGASUS — the
Phase 3 Trial
of
Rilzabrutinib

PEGASUS is a global, randomized, double-blind, placebo-controlled, pivotal, Phase 3 clinical trial enrolling approximately 120 participants to evaluate rilzabrutinib versus placebo, using a background treatment of tapering doses of corticosteroids (CS). The trial entry criteria include participants with moderate to severe pemphigus who are either newly diagnosed or relapsing with chronic disease. This demographic will potentially represent three quarters of the pemphigus patient population. The primary efficacy endpoint is the ability of rilzabrutinib to achieve durable complete remission (CR) at 37 weeks of treatment. Durable CR is defined as a state in which all lesions have healed on very low dose CS (5mg/day), and no new lesions have appeared for a period of at least eight weeks. Key secondary endpoints include cumulative CS use and time to CR. At 37 weeks, all patients will have the option to be treated with active rilzabrutinib therapy in an open-label extension period of 24 weeks. Rilzabrutinib has been granted orphan drug designation by the U.S. Food and Drug Administration and the European Commission for the treatment of patients with pemphigus.

About
rilzabrutinib

Rilzabrutinib is an oral, reversible covalent, Bruton tyrosine kinase (BTK) inhibitor being investigated for the treatment of immune mediated diseases. BTK is involved in innate and adaptive immune responses and is a signaling molecule in immune mediated diseases. Rilzabrutinib data demonstrates an ability to block inflammatory immune cells, eliminate autoantibody destructive signaling, and prevent new autoantibody production without depleting B cells. Rilzabrutinib is currently under clinical development, and its safety and efficacy have not been reviewed by any regulatory authority.

About Pemphigus

According to the International Pemphigus and Pemphigoid Foundation, pemphigus is a group of potentially life-threatening disorders characterized by blisters in mucous membranes and skin. The blistering in pemphigus happens because of an immune response resulting in autoantibodies attacking the “glue” that holds mucous membranes or skin cells together. This process is called “acantholysis” and is not fully understood. Pemphigus patients develop mucosal erosions and/or blisters, erosions, or small bumps that fill with pus or fluid. The four major types of pemphigus include pemphigus vulgaris, pemphigus foliaceus, IgA pemphigus, and paraneoplastic pemphigus. The most common form of pemphigus is pemphigus vulgaris; however, in some areas of the world, pemphigus foliaceus is more prevalent. Pemphigus vulgaris is generally more severe than pemphigus foliaceus. Pemphigus vulgaris usually involves a lot of blisters and erosions. In pemphigus foliaceus, blistering is more superficial than pemphigus vulgaris.

About Principia Biopharma

Principia, a Sanofi company, is dedicated to bringing transformative therapies to patients with significant unmet medical needs in immune mediated diseases. Through Principia’s proprietary Tailored Covalency^® platform, our strategy is to build and advance a pipeline of drug candidates with significant therapeutic benefits, limit unintended side effects, improve quality of life and over time modify the course of disease. The company is pursuing three drug candidates. Rilzabrutinib, a reversible covalent BTK inhibitor, is being evaluated in a global Phase 3 clinical trial in pemphigus, a Phase 1/2 and Phase 3 clinical trial in immune thrombocytopenia (ITP), and a Phase 2A clinical trial in IgG4-RD. Tolebrutinib (SAR442168) is a covalent BTK inhibitor which crosses the blood-brain barrier and has entered Phase 3 clinical trials in multiple sclerosis. PRN473 Topical, a topical reversible covalent BTK inhibitor is being evaluated in Phase 1 trials. For more information, please visit www.principiabio.com.

Media Contact

Bernadette Wang, Associate Director, Corporate Communications and Patient Advocacy
[email protected]
650-636-5039

Ashleigh Koss, VP, Head of Global Media Relations
[email protected]
908-205-2572

TEMPLE CITY, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) — Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that its Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim, and Chief Commercial Officer Brandon Perthuis virtually participated in a pre-recorded fireside chat that will be published as part of the Piper Sandler 32^nd Annual Healthcare Conference taking place December 1 to 3, 2020. Management will also be conducting virtual one-on-one investor meetings during the conference.

A webcast of the fireside chat will be available on the Investor Relations section of the Fulgent Genetics website at ir.fulgentgenetics.com, and will be available for 90 days following the conference.

About
Fulgent Genetics

Fulgent Genetics’ proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy and competitive turnaround times. Combining next generation sequencing (“NGS”) with its technology platform, the company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. In 2019, the company launched its first patient-initiated product, Picture Genetics, a new line of at-home screening tests that combines the company’s advanced NGS solutions with actionable results and genetic counseling options for individuals. Since March 2020, the company has commercially launched several tests for the detection of SARS-CoV-2, the virus that causes the novel coronavirus (“COVID-19”), including NGS and reverse transcription polymerase chain reaction (“RT-PCR”) – based tests. The company has received Emergency Use Authorization (“EUA”) from the U.S. Food and Drug Administration (“FDA”) for the RT-PCR-based tests for the detection of SARS-CoV-2 using upper respiratory specimens (nasal, nasopharyngeal, and oropharyngeal swabs) and for the at-home testing service through Picture Genetics. A cornerstone of the company’s business is its ability to provide expansive options and flexibility for all clients’ unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service and automated laboratory services.

Investor Relations Contact
s
:

The Blueshirt Group
Nicole Borsje, 415-217-2633; [email protected]

GREENSBORO, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) — Qorvo® (Nasdaq: QRVO), a leading provider of innovative RF solutions that connect the world, today announced that Company executives are scheduled to present at the Wells Fargo Tech, Media & Telecom (“TMT”) Virtual Summit on Tuesday, December 1, 2020 at 10:00 a.m. ET.

A live webcast of the virtual event will be available on the Company’s web site at the following URL: http://www.qorvo.com (under “Investors”).

About Qorvo

Qorvo (Nasdaq: QRVO) makes a better world possible by providing innovative Radio Frequency (RF) solutions at the center of connectivity. We combine product and technology leadership, systems-level expertise and global manufacturing scale to quickly solve our customers’ most complex technical challenges. Qorvo serves diverse high-growth segments of large global markets, including advanced wireless devices, wired and wireless networks and defense radar and communications. We also leverage unique competitive strengths to advance 5G networks, cloud computing, the Internet of Things, and other emerging applications that expand the global framework interconnecting people, places and things. Visit www.qorvo.com to learn how Qorvo connects the world.

Qorvo is a registered trademark of Qorvo, Inc. in the U.S. and in other countries. All other trademarks are the property of their respective owners.

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions, and are not historical facts and typically are identified by use of terms such as “may,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements included herein represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those expressed or implied by forward-looking statements. We do not intend to update any of these forward-looking statements or publicly announce the results of any revisions to these forward-looking statements, other than as is required under U.S. federal securities laws. Our business is subject to numerous risks and uncertainties, including those relating to fluctuations in our operating results; our substantial dependence on developing new products and achieving design wins; our dependence on a few large customers for a substantial portion of our revenue; a loss of revenue if contracts with the United States government or defense and aerospace contractors are canceled or delayed or if defense spending is reduced; the COVID-19 pandemic, which has and will likely continue to negatively impact the global economy and disrupt normal business activities, and which may have an adverse effect on our results of operations; our dependence on third parties; risks related to sales through distributors; risks associated with the operation of our manufacturing facilities; business disruptions; poor manufacturing yields; increased inventory risks and costs due to timing of customer forecasts; our inability to effectively manage or maintain evolving relationships with platform providers; risks from international sales and operations; economic regulation in China; changes in government trade policies, including imposition of tariffs and export restrictions; our ability to implement innovative technologies; underutilization of manufacturing facilities as a result of industry overcapacity; we may not be able to borrow funds under our credit facility or secure future financing; we may not be able to generate sufficient cash to service all of our debt; restrictions imposed by the agreements governing our debt; volatility in the price of our common stock; damage to our reputation or brand; fluctuations in the amount and frequency of our stock repurchases; our recent and future acquisitions and other strategic investments could fail to achieve financial or strategic objectives; our ability to attract, retain and motivate key employees; our reliance on our intellectual property portfolio; claims of infringement of third-party intellectual property rights; security breaches and other similar disruptions compromising our information; theft, loss or misuse of personal data by or about our employees, customers or third parties; warranty claims, product recalls and product liability; and risks associated with environmental, health and safety regulations and climate change. Many of the foregoing risks and uncertainties are, and will continue to be, exacerbated by the COVID-19 pandemic and any worsening of the global business and economic environment as a result. These and other risks and uncertainties, which are described in more detail in Qorvo’s most recent Annual Report on Form 10-K and in other reports and statements filed with the Securities and Exchange Commission, could cause actual results and developments to be materially different from those expressed or implied by any of these forward-looking statements.

At Qorvo®
Doug DeLieto
VP, Investor Relations
1- 336-678-7968

CASTLE ROCK, Colo., Nov. 24, 2020 (GLOBE NEWSWIRE) — Where Food Comes From, Inc. (WFCF) (OTCQB: WFCF), the most trusted resource for independent, third-party verification of food production practices in North America, today announced it plans to implement a 1-for-4 reverse split of its common stock that will be effective after the market closes on Monday, November 30, 2020. The Company also announced it intends to uplist its shares to Nasdaq.

“The Board of Directors and management are pleased to announced plans to uplist our shares to the Nasdaq Capital Market,” said John Saunders, chairman and CEO of WFCF. “We believe that elevating our shares to the country’s premier exchange will raise our profile in the broader investment community and increase our appeal to institutional investors, ETFs and indexes. The planned uplisting together with the reverse stock split should make WFCF more attractive to investors that may have been prohibited from purchasing our shares due to certain restrictions on trading in lower priced stocks that are not listed on a major exchange. We appreciate the overwhelming support of our shareholders who authorized the reverse split.”

At the Annual Meeting of Stockholders on May 13, 2019, WFCF stockholders approved a reverse stock split of not more than 1-for-4 as determined by the WFCF Board. The primary purpose of the reverse split is to raise the Company’s share price to a level that meets the initial listing standards of the Nasdaq Capital Market.

The reverse split would result in each stockholder owning one share of stock for every four shares of stock previously owned. Following the reverse split, and except for adjustments that may result from the treatment of fractional shares that will be rounded up: 1) each stockholder will hold the same percentage of outstanding common stock as such stockholder held immediately prior to the reverse split; and 2) WFCF will have approximately 6,159,935 common shares outstanding compared to approximately 24,639,737 common shares outstanding immediately prior to the reverse split.

WFCF has initiated the application process for the Nasdaq Capital Market and is working with Nasdaq representatives to complete the uplisting process as soon as practicable. WFCF will issue a news release once a target date for uplisting has been established.

CAUTIONARY STATEMENT
This news release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, based on current expectations, estimates and projections that are subject to risk. Forward-looking statements are inherently uncertain, and actual events could differ materially from the Company’s predictions. Important factors that could cause actual events to vary from predictions include those discussed in our SEC filings. Specifically, statements in this news release about plans and timetables for effecting a reverse split and uplisting to Nasdaq; the potential to attract raise WFCF’s profile and new investors; industry leadership; and demand for, and impact and efficacy of, the Company’s products and services on the marketplace are forward-looking statements that are subject to a variety of factors, including availability of capital, personnel and other resources; competition; governmental regulation of the agricultural industry; the market for beef and other commodities; and other factors. Readers should not place undue reliance on these forward-looking statements. The Company assumes no obligation to update its forward-looking statements to reflect new information or developments. For a more extensive discussion of the Company’s business, please refer to the Company’s SEC filings at www.sec.gov.

Company Contacts:

John Saunders
Chief Executive Officer
303-895-3002

Jay Pfeiffer
Pfeiffer High Investor Relations, Inc.
303-880-9000

GAITHERSBURG, Md., Nov. 24, 2020 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced it has entered into a definitive agreement for a private placement with one healthcare-focused U.S. institutional investor of (i) 2,245,400 shares of common stock together with 2,245,400 warrants (the “Common Warrants”) to purchase up to 2,245,400 shares of common stock and (ii) 2,597,215 pre-funded warrants (the “Pre-Funded Warrants”), with each Pre-Funded Warrant exercisable for one share of common stock, together with 2,597,215 Common Warrants to purchase up to 2,597,215 shares of common stock. Each share of common stock and accompanying Common Warrant are being sold together at a combined offering price of $2.065, and each Pre-funded Warrant and accompanying Common Warrant are being sold together at a combined offering price of $2.055. The Pre-Funded Warrants are immediately exercisable, at an exercise price of $0.01, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Common Warrants will have an exercise price of $1.94 per share, will be exercisable commencing on the six month anniversary of the date of issuance, and will expire five and one half (5.5) years from the date of issuance (collectively, the “Private Placement”).

The Private Placement is expected to close on or about November 25, 2020, subject to the satisfaction of customary closing conditions and the receipt of regulatory approvals, including the approval of the Nasdaq Capital Market.

A.G.P./Alliance Global Partners is acting as sole placement agent for the Private Placement.

The Private Placement is being made in the United States pursuant to the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 of Regulation D as promulgated by the United States Securities and Exchange Commission (SEC). The securities to be sold in the Private Placement have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws, and accordingly may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issued in the Private Placement, as well as the shares of common stock issuable upon exercise of the Warrants and pre-funded warrants issued in the Private Placement.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities hereunder nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

ABOUT
OPGEN,
INC.

OpGen, Inc. (Gaithersburg, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s product portfolio includes Unyvero, Acuitas AMR Gene Panel and Acuitas® Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.

For more information, please visit www.opgen.com.

FORWARD LOOKING STATEMENTS
by OPGEN
:

This press release includes forward looking statements regarding the Private Placement. These statements and other statements regarding OpGen’s future plans and goals constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. For example, the expected date of closing of the Private Placement is a forward looking statement. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our use of proceeds from the Private Placement and that we may not use such proceeds effectively, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the realization of expected benefits of our business combination transaction with Curetis GmbH, the success of our commercialization efforts, the impact of COVID-19 on the Company’s operations, financial results, and commercialization efforts as well as on capital markets and general economic conditions, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen’s business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

OpGen Contact:

Oliver Schacht
CEO
[email protected]

Press Contact:

Matthew Bretzius
FischTank Marketing and PR
[email protected]

Investor Contact:

Megan Paul
Edison Group
[email protected]

SEATTLE, Nov. 24, 2020 (GLOBE NEWSWIRE) — SEngine Precision Medicine, a precision oncology company revolutionizing cancer diagnostics and therapies by pre-testing drugs on patient-derived tumor organoids, today announced that data from a study summarizing the predictive value of the PARIS® Test in breast cancer patients will be presented virtually as a poster session (PS04/01) at the 2020 San Antonio Breast Cancer Symposium.

Details related to the poster presentation are as follows:
Title: Clinical and genomic correlation of a CLIA certified organoid based functional test in breast cancer patients
Lead Author: Astrid Margossian, MD, PhD
Senior Author: Carla Grandori, MD, PhD
Poster Session: Poster Session 4: Response Prediction Biomarkers I (PS04/01)
Poster Session Date: December 9, 2020 at 8:00 am CT

About the PARIS® Test 
The PARIS® Test is based on the capability to propagate patient-specific cancer cells as organoids outside the body and is applicable to all solid tumors including colon, breast, lung, ovarian and pancreatic cancer. Organoids are cancer-derived cells grown in 3D outside the body, which maintain the functionality of the original tumor as well as its genomic characteristics. For cancers where a treatment path is not clear, such as many metastatic and recurrent cancers, the PARIS® Test provides crucial information to treating physicians to match the right drug to the right patient.

About
SEngine
Precision Medicine

SEngine Precision Medicine Inc. is a precision oncology company revolutionizing cancer diagnostics and therapies by pre-testing drugs on patient-derived organoids grown ex-vivo utilizing patient specific tumor cells. As a spin-out from the world-renowned Fred Hutchinson Cancer Research Center, SEngine is leveraging over two decades of R&D in diagnostics and drug discovery. The Company is commercializing the PARIS® Test, a next generation diagnostic test that predicts drug responses integrating knowledge of cancer genomics with organoids, robotics, and AI-driven computational tools. SEngine’s CLIA certified PARIS® Test generates predictive drug sensitivity reports for patients with solid tumors. SEngine is also pursuing drug discovery via strategic collaborations with biopharmaceutical / pharma companies leveraging its precision oncology platform.

Discover more at SEngineMedicine.com and follow the latest news from SEngine on Twitter at @SEngineMedicine and on LinkedIn.

Contact:

Stephanie Carrington
[email protected]
646-277-1282 

SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) — Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1, 2020 at 3:30 p.m. ET.

A live webcast will be accessible via the Events page of the Applied Molecular Transport website at https://ir.appliedmt.com/news-events/events. An archived replay will be available for 30 days following the event.

About Applied Molecular Transport Inc.

Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. AMT’s proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of diverse therapeutic modalities across the intestinal epithelium (IE) barrier. Active transport is an efficient mechanism that uses the cell’s own machinery to transport materials across the IE barrier. AMT believes that its ability to exploit this mechanism is a key differentiator of its approach. AMT is developing additional oral biologic product candidates in patient-friendly tablet and capsule forms that are designed to either target local gastrointestinal tissue or enter systemic circulation to precisely address the relevant biology of a disease.

AMT’s headquarters, internal GMP manufacturing and lab facilities are located in South San Francisco, CA. For additional information on AMT, please visit www.appliedmt.com.

Investor Relations


Contact:


Andrew Chang
Head, Investor Relations & Corporate Communications
[email protected]

Media Contacts:


Alexandra Santos
Wheelhouse Life Science Advisors
[email protected]

Aljanae Reynolds
Wheelhouse Life Science Advisors
[email protected]

CAMBRIDGE, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) — Oncorus, Inc. (Nasdaq:ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, announced today that Theodore (Ted) A. Asbhurn, M.D., Ph.D., President and Chief Executive Officer, will participate in fireside chats at two upcoming investor conferences.

32

^nd

Annual
Piper Sandler Annual
Virtual
Healthcare Conference

Dates: December 1 – December 3, 2020
Webcast: The pre-recorded fireside chat is now available in the Investors & Media section of Oncorus’ website at https://investors.oncorus.com/events-and-presentations. The presentation will be archived on the company’s site for 90 days.

3rd Annual
 
Evercore ISI
HealthCONx
Conference

Date: December 3, 2000
Time: 9:40 a.m. ET
Webcast: A live webcast of the presentation will be available in the Investors & Media section of Oncorus’ website at https://investors.oncorus.com/events-and-presentations. A replay of the presentation will be archived on the company’s site.

About Oncorus

At Oncorus, we are focused on driving innovation to deliver next-generation viral immunotherapies to transform outcomes for cancer patients. We are advancing a portfolio of intratumorally and intravenously administered viral immunotherapies for multiple indications with significant unmet needs based on our oncolytic Herpes Simplex Virus (oHSV) Platform and Synthetic Virus Platform. Designed to deliver next-generation viral immunotherapy impact, our oHSV platform improves upon key characteristics of this therapeutic class to enhance potency without sacrificing safety, including greater capacity to encode transgenes to drive systemic immunostimulatory activity, retention of full replication competency to enable high tumor-killing potency, and orthogonal safety strategies to restrict viral activity in tumor cells. Our lead oHSV program, ONCR-177, is designed to be directly administered into a tumor, resulting in high local concentrations of the therapeutic agent, as well as low systemic exposure to the therapy, which we believe could potentially limit systemic toxicities. Please visit www.oncorus.com to learn more.

Investor Contact:	Media Contact:
Alan Lada	Liz Melone
Solebury Trout	[email protected]
617-221-8006
[email protected]